Posterior scleritis is an unusual condition that is most commonly seen in middle-aged women.
1 , 2 The protean manifestations and the range of severity of the condition can lead to delay in diagnosis and subsequent loss of vision. Its occurrence in children is rare, with only 14 cases reported in the literature.
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Reported cases have ranged in severity from mild cases treated with non-steroidal anti-inflammatory agents to cases with visual loss due to optic atrophy.
We report a further 5 children with severe posterior scleritis who required treatment with high-dose immunosuppression.
PATIENTS AND METHODS
Five children were diagnosed as having posterior scleritis over a 9 month period at the Medical Eye
Unit at St Thomas' Hospital. All patients underwent a complete ophthalmic and general examination with The antibiotics were stopped and the patient was started on oral prednisolone 60 mg once daily (1 mg! kg) and ranitidine 150 mg twice daily with rapid improvement.
The patient was discharged home on 40 mg/day prednisolone but returned the next day complaining of pain in both eyes. On examination at that time visual acuity was 6/9 in each eye and both eyes showed 2+ cells in the anterior chamber. Since then the patient has been followed up for a further 9 months and the re-introduction of cyclos porin A has allowed the prednisolone to be gradually reduced with only minor relapses. She is currently taking cyclosporin A 75 mg twice daily, prednisolone 10 mg once on alternate days, and topical steroids as necessary. Visual acuity remained at 6/9 right, 6/6 left, and the fundal signs had resolved.
Summary of Cases
The clinical results of the patients are summarised in The diagnosis may be made on the basis of B-scan ultrasonography, which showed scleral thickening in all 5 of our cases. However, scleral thickening can also be produced by acute pseudo-tumour of the orbit and for this reason we also performed CT scans of the orbit ?
All the cases in this series required high-dose immunosuppression to control the disease and prevent relapse. In 2 cases non-steroidal anti inflammatory agents had been tried without suc cess. Immunosuppression with prednisolone alone was tried in all patients but in 4 cases it was not possible to reduce the dose below 30 mg once daily without precipitating relapse, and in 2 cases the patients became overtly cushingoid and increased their body weight by at least a quarter. In one case prednisolone on alternate days was tried, to reduce the incidence of steroidal side effects, but this was not found to be as effective as a once daily dosage. In the cases requiring high-dose prednisolone and where medical complications intervened, cyclos porin A at a dose of 5 mg/kg was introduced as a steroid sparing agent. In all cases this second-line immunosuppression allowed the steroids to be reduced to a tolerable level for maintenance of therapy. In case 5 the drug needed to be stopped due to the development of proteinuria which was subsequently found to be due to a urinary tract infection. However, on re-introduction no further problems were found and thus cyclosporin A is both a useful and well-tolerated adjunct to prednisolone in children.
